Heart rate

Sepsis: why this deadly condition is so hard to diagnose

Retrieved on: 
måndag, juni 3, 2024
Sepsis, Patient, Fever, Coma, Infection, Blood pressure, Immune system, Death, Prevalence, Science Foundation Ireland, Diabetes, Genetically modified bacteria, Dialysis, Chills, Cancer, Health, Risk, Amputation, Tissue, Research, Bacteria, Hospital, Survival, Parasitism, Biomarker, COVID, Fungus, Survival rate, Virus, Abdomen, Shutterstock, Asthma, Hygiene, Hope, Disease, Arthritis, CC, Heart rate, Irish Research Council, Abscess, MacKinlay, System, Commons, Blood, Septic shock, Oxygen, Health Research Board, Vaccine

Last September, Mackinlay said he’d begun feeling unwell – but didn’t think anything of his symptoms, especially after testing negative for COVID.

Key Points: 
  • Last September, Mackinlay said he’d begun feeling unwell – but didn’t think anything of his symptoms, especially after testing negative for COVID.
  • But his condition quickly worsened throughout the night.
  • When Mackinlay was finally admitted to hospital the following day, his entire body had turned blue.
  • Sepsis is a severe condition that arises when the body’s response to an infection injures its own tissues and organs.

Severe condition

  • There are numerous reasons why sepsis is such a dangerous condition.
  • Yet these subtle signs can turn severe within hours because of how rapidly sepsis progresses.
  • And, because of sepsis’s complex nature, it lacks a biological signature (or biomarker) that can reliably be used to diagnose the condition.
  • But these signs don’t always clearly indicate the presence of the condition – at least initially.

Future of treatment

DeRing, the World's First AI+Web3 Smart Ring Brand, Officially Launches Website

Retrieved on: 
torsdag, maj 30, 2024
Nifedipine, Big, Sleep, Exercise, Heart rate, Health, DAO, NFC, Apple, Decentralized autonomous organization, AI, Samsung, Mobile phone

According to Data Horizzon Research , the smart ring market is expected to reach $1.4051 billion by 2032.

Key Points: 
  • According to Data Horizzon Research , the smart ring market is expected to reach $1.4051 billion by 2032.
  • Meanwhile, tech giants like Samsung and Apple are entering the smart ring market, making the market outlook even brighter.
  • Market research firms have predicted that the global smart ring market will reach a staggering $11.9 billion by 2027.
  • As the hardware evolved, the development incorporated Web3 incentive models and AI algorithm concepts, making it the earliest Web3×AI wearable smart ring DePIN project.

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

Retrieved on: 
onsdag, maj 22, 2024
Patient, Disease, Diagnosis, Paroxysmal supraventricular tachycardia, Education, Heart, BST, Heart failure, Palpitations, EDT, Anxiety, Heart rate, Dizziness, Life, Weill Cornell Medical Center, Lightheadedness, Coffee, Chronic pain, SVT, Dehydration, Arrhythmia, Supraventricular tachycardia, PSVT, Cardiology, Periodic breathing, Pharmaceutical industry

MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT).

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT).
  • SVT Awareness Day will be held on Wednesday June 5, 2024, during World Heart Rhythm Week (June 4-10), to raise awareness of SVT, a type of arrhythmia or rapid heart rhythm that leaves people with palpitations (“racing heart rate”), breathlessness, and anxiety.
  • “We are honored to partner with the Arrhythmia Alliance on educational initiatives for SVT Awareness Day.
  • For additional information on SVT, visit SVT Heart to Heart provided by Milestone Pharmaceuticals.

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
tisdag, maj 14, 2024
Plasma, SOC, Risk, FDA, Ageing, Electrocardiography, Week, Fast Track, HCV, Kinetics, RNA, Research, QRS, Standard of care, QT, Bemnifosbuvir, Patient, QT interval, Infection, Cardiotoxicity, SVR4, Security (finance), Second generation, Administration, COVID-19, Food, Clinical trial, Viral, Safety, Hospital, Viral load, SVR, Doctor of Philosophy, NS5A, EASL, BID, Heart rate, Tax, NS5B, Immunodeficiency, Death, Cirrhosis, PR, Development, Pharmaceutical industry

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Final results from the 60-patient lead-in cohort confirmed a 98% SVR4 rate across all genotypes from 58 of 59 patients.
  • Topline results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • In April 2024, Atea presented Phase 1 data showing that bemnifosbuvir does not alter cardiac repolarization.

Study in the Journal of the American Heart Association Links Hello Heart Usage to Significant Reductions in Blood Pressure, Cholesterol, and Weight

Retrieved on: 
måndag, maj 20, 2024
Cardiology, Software, Health, Artificial Intelligence, Health Technology, Technology, Apps, Applications, Mobile, Wireless, Blood pressure, Cardiovascular disease, Risk, TC, American Heart Association, Obesity, Apolipoprotein, Heart rate, SVP, Stroke, Death, Hypertension, SBP, CVD, Journal, Mortality, Human, Artificial intelligence, BMI, Disability, Cholesterol, Medicine

A new peer-reviewed study in the Journal of the American Heart Association found that Hello Heart ’s digital heart health program was associated with reductions in blood pressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight.

Key Points: 
  • A new peer-reviewed study in the Journal of the American Heart Association found that Hello Heart ’s digital heart health program was associated with reductions in blood pressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight.
  • The study is the largest and most robust of its kind to date, examining 102,475 Hello Heart users with high BP (hypertension) between January 2018 and December 2022.
  • Users were equipped with Hello Heart’s connected heart health monitor and mobile app with digital coaching.
  • The Hello Heart monitor and app recorded BP, heart rate, and the appearance of irregular heartbeat.

Tivic Reports First Quarter 2024 Financial Results and Subsequent Events

Retrieved on: 
onsdag, maj 15, 2024
Consumer Electronics, Health, Medical Devices, Technology, Health Technology, General Health, Biotechnology, Security (finance), Intellectual property, Average cost, Commission, Medical research, Post-traumatic stress disorder, Supply chain, Depression, Telephone, Trial of the century, Heart rate, Bank statement, Stroke, EBay, Target, Walmart, Form, Psychiatry, Epilepsy, Northwell Health, Neurology, Vagus nerve stimulation, Kroger, Form S-1, System, VNS, Cardiology, Pharmaceutical industry

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events.
  • On May 8, 2024, the Company announced the final results of their pilot research study with The Feinstein Institutes for Medical Research at Northwell Health.
  • The company’s MD&A and consolidated financial statements for the quarter ended March 31, 2024 will be filed with the Securities and Exchange Commission on May 15, 2024 with the company’s Quarterly Report on Form 10-Q.
  • Management will host a webcast/conference call on Wednesday, May 15, 2024, at 1:30 PM PT / 4:30 PM ET to discuss the company’s first quarter 2024 financial results and provide a business update, including comments on the direction the company is heading in 2024.

Feinstein Institutes Use Brainstem Vagus Nerve Stimulation to Reduce Inflammation With or Without a Decrease in Heart Rate

Retrieved on: 
onsdag, maj 15, 2024
COVID-19, Research, Neurology, Genetics, Diabetes, Biotechnology, Health, Science, Oncology, Other Science, Paper, Credit, Sepsis, Inflammation, Nervous system, Doctor of Philosophy, Survival, Neuroscience, Medical research, Sensation, Risk, Paralysis, Immunity, Immune system, Heart rate, Disease, Molecular medicine, Fatality, Vagus nerve, Mouse, Feinstein, Death, Cancer, Medicine, Vagus nerve stimulation, Behavior, Arthritis, Pulmonary hypertension, Crohn's disease, Inflammatory Bowel Diseases, Interface (computing), Biomedical engineering, Multimedia, Rheumatoid arthritis, Infection

A new study published in Brain, Behavior and Immunity by The Feinstein Institutes for Medical Research researchers shows that stimulation of the brainstem region where the vagus nerve originates, could help reduce inflammation and heart rate, and improve survival.

Key Points: 
  • A new study published in Brain, Behavior and Immunity by The Feinstein Institutes for Medical Research researchers shows that stimulation of the brainstem region where the vagus nerve originates, could help reduce inflammation and heart rate, and improve survival.
  • This preclinical research opens new therapeutic avenues to address inflammation, and in turn, find ways to suppress heart rate by using vagus nerve stimulation in the brainstem.
  • The results show that this stimulation could lower heart rate and reduce inflammation significantly.
  • They also found that even a regimen of stimulation, which does not affect the heart rate, also suppresses inflammation and improves survival.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
torsdag, maj 9, 2024
Accelerometer, Research, Sensor, Wi-Fi, ECG, Cardiology, Biomaterial, Privacy, Boston Scientific, Diagnosis, Skin, IHME, Food, BLE, Flow measurement, Blood pressure, Ageing, Environmental monitoring, Statistics, Diabetes management, Diabetes, CGM, Medicine, World Economic Forum, Wireless, Bluetooth Low Energy, Blood, Temperature, Health care, Component, Wearable, Data, Bluetooth, NFC, Sport, Heart rate, POC, Fitness, Medical device

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points: 
  • Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
  • Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
torsdag, maj 9, 2024
Accelerometer, Research, Sensor, Wi-Fi, ECG, Cardiology, Biomaterial, Privacy, Boston Scientific, Diagnosis, Skin, IHME, Food, BLE, Flow measurement, Blood pressure, Ageing, Environmental monitoring, Statistics, Diabetes management, Diabetes, CGM, Medicine, World Economic Forum, Wireless, Bluetooth Low Energy, Blood, Temperature, Health care, Component, Wearable, Data, Bluetooth, NFC, Sport, Heart rate, POC, Fitness, Medical device

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points: 
  • Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
  • Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
onsdag, maj 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.